Latanoprost

also known as Xalatan · PhXA41 · T-2345 · Monoprost · alphagan-P · Catioprost · D565H · GAAP Ofteno · +13 more

Developed for: ocular hypertension · open-angle glaucoma · glaucoma · borderline glaucoma · diabetic retinopathy · eye adnexa disorder · myopia · androgenetic alopecia
+11 more
· bullous keratopathy · chronic closed-angle glaucoma · congenital glaucoma · endocrine exophthalmos · hypotrichosis · Meniere disease · vitiligo · alopecia areata · exfoliation syndrome · low tension glaucoma · vascular disorder
Investigated by: Viatris Inc. · Mati Therapeutics Inc. · Alcon Research · Pfizer · University of Nebraska · Aerie Pharmaceuticals
+63 more
· Laboratoires Thea · National Eye Institute (NEI) · Pharmaceutical Research Network · Aristotle University Of Thessaloniki · Chong Kun Dang Pharmaceutical · Hoffmann-La Roche · Laboratorios Sophia S.A de C.V. · Mayo Clinic · Merck Sharp & Dohme LLC · PolyActiva Pty Ltd · QLT Inc. · Santen SAS · Sun Yat-sen University · University of Aarhus · Zagazig University · Aarhus University Hospital · Adapt Produtos Oftalmológicos Ltda. · Advanced Glaucoma Specialists · Afyon Kocatepe University Hospital · Allergan · Aneira Pharma, Inc. · Association for Innovation and Biomedical Research on Light and Image · Aurolab · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Bausch & Lomb Incorporated · CHU de Quebec-Universite Laval · Canadian Glaucoma Clinical Research Council · Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Chittagong Medical College · Credit Valley EyeCare · Dr. David Yan · European Vision Institute Clinical Research Network · Glostrup University Hospital, Copenhagen · IUVO S.r.l. · Julie Dawson · Laboratorios Poen · Nanduri, Padma, M.D., FACS · Nephron Pharmaceuticals Corporation · Ohio State University · Padjadjaran University · Peking University First Hospital · Robin, Alan L., M.D. · Santen Pharmaceutical (Taiwan) Co., LTD · Singapore Eye Research Institute · Stanford University · Synphora AB · Triple Hair Inc · Umeå University · Universiti Kebangsaan Malaysia Medical Centre · University Hospital Centre Zagreb · University Hospital Dubrava · University Hospital, Basel, Switzerland · University of Campinas, Brazil · University of Maryland, Baltimore · University of Miami · University of Michigan · University of Milan · University of Zagreb · University of the Incarnate Word · Uzoma Chinyei Joan · ViSci Ltd. · Wills Eye · Yale University

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Roclanda	—	2021-01-07	europa.eu ↗
Label expansion	US (FDA)	XALATAN	—	2002-12-20	fda.gov ↗
Label expansion	US (FDA)	ALPHAGAN P	—	2001-12-20	fda.gov ↗
Approved	US (FDA)	XALATAN	—	1996-06-05	fda.gov ↗

Trials 109 · started per year

today

US approved 1996

EU approved 2021

1992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06730516	Jun → Sep 2024	glaucoma	Zagazig University	Completed	No outcome recorded
Phase 0	NCT05790941	Mar → Jun 2023	hypotrichosis	Aneira Pharma, Inc.	Unknown	No outcome recorded
Phase 0	NCT04234932	Jan 2020 → Jan 2021	open-angle glaucoma	University of the Incarnate Word	Unknown	No outcome recorded
Phase 15 trials
Phase 1	NCT06629129	Jun → Aug 2024	—	Zagazig University	Completed	No outcome recorded
Phase 1	NCT04060758	Mar 2020 → May 2025	open-angle glaucoma	PolyActiva Pty Ltd	Completed	No outcome recorded
Phase 1	NCT03293992	Oct → Dec 2017	ocular hypertension, open-angle glaucoma	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT02622334	Dec 2015 → Jul 2016	glaucoma	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT00638742	May 2008 → Mar 2009	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02129673	May 2014 → May 2017	ocular hypertension, open-angle glaucoma	ViSci Ltd.	Completed	No outcome recorded
Phase 1/2	NCT01987323	Jan → Jun 2013	ocular hypertension	Singapore Eye Research Institute	Completed	No outcome recorded
Phase 232 trials
Phase 2	NCT07016113	Jul → Oct 2025 overdue	vitiligo	Padjadjaran University	Not yet recruiting	No outcome recorded
Phase 2	NCT06964191	May 2025 → Nov 2026 expected	ocular hypertension, open-angle glaucoma	PolyActiva Pty Ltd	Active not recruiting	No outcome recorded
Phase 2	NCT04448223	Jun 2020 → Dec 2022	ocular hypertension, open-angle glaucoma	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 2	NCT04205201	Jun 2018 → Sep 2019	—	Chittagong Medical College	Completed	No outcome recorded
Phase 2	NCT03067415	Mar → Sep 2017	ocular hypertension, open-angle glaucoma	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 2	NCT03292796	Dec 2016 → Oct 2019	open-angle glaucoma	Julie Dawson	Completed	No outcome recorded
Phase 2	NCT02057575	Jan → Jun 2014	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02014142	Dec 2013 → Dec 2016	ocular hypertension, open-angle glaucoma	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT01973114	Oct 2013 → May 2016	Meniere disease	Synphora AB	Unknown	No outcome recorded
Phase 2	NCT01481051	Nov 2011 → Sep 2012	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT01481077	Nov 2011 → Sep 2012	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT01426464	Sep → Nov 2011	glaucoma	Nanduri, Padma, M.D., FACS	Unknown	No outcome recorded
Phase 2	NCT01254370	Nov 2010 → Jun 2011	eye adnexa disorder, glaucoma, ocular hypertension	Santen SAS	Completed	No outcome recorded
Phase 2	NCT01229982	Oct 2010 → Aug 2011	ocular hypertension, open-angle glaucoma	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT01060579	Feb → Aug 2010	glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00934089	Jan → Jun 2010	ocular hypertension, open-angle glaucoma	Pfizer	Completed	No outcome recorded
Phase 2	NCT01037036	Dec 2009 → Apr 2010	ocular hypertension, open-angle glaucoma	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT00967811	Aug 2009 → May 2010	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT01527682	Jul 2009 → Nov 2016	congenital glaucoma	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Completed	No outcome recorded
Phase 2	NCT00855517	Mar → Jul 2009	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Withdrawn	No outcome recorded
Phase 2	NCT00845299	Jan → Dec 2009	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT00820300	Jan → Dec 2009	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT00821002	Jan → Nov 2009	ocular hypertension, open-angle glaucoma	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT01494753	Jun → Dec 2008	open-angle glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 2	NCT00650702	Mar 2008 → Feb 2009	glaucoma, ocular hypertension	Mati Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT00572455	Dec 2007 → Jun 2009	ocular hypertension, open-angle glaucoma	Pfizer	Completed	No outcome recorded
Phase 2	NCT00595101	Dec 2007 → Jun 2008	ocular hypertension, open-angle glaucoma	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 2	NCT00465621	Mar → Jul 2007	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT00572936	Mar 2006 → Nov 2009	glaucoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT00579969	Dec 2003 → Oct 2008	glaucoma	University of Nebraska	Terminated	No outcome recorded
Phase 2	NCT01379144	Jan → Mar 2003	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 2	NCT00143429	—	ocular hypertension, open-angle glaucoma	Viatris Inc.	Withdrawn	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT06960629	Jan 2025 → Apr 2026	bullous keratopathy, glaucoma	University Hospital Dubrava	Completed	No outcome recorded
Phase 325 trials
Phase 3	NCT07435012	Apr 2026 → Dec 2027 expected	androgenetic alopecia	Triple Hair Inc	Recruiting	No outcome recorded
Phase 3	NCT04133311	Apr 2019 → Feb 2022	eye adnexa disorder, open-angle glaucoma	Santen SAS	Completed	No outcome recorded
Phase 3	NCT03284853	Sep 2017 → Nov 2020	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02390284	Sep 2015 → Oct 2024	glaucoma	University of Miami	Terminated	No outcome recorded
Phase 3	NCT02801617	Sep 2015 → Mar 2017	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Terminated	No outcome recorded
Phase 3	NCT02059278	Jan 2014 → Jan 2015	ocular hypertension, open-angle glaucoma	Nephron Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 3	NCT01721707	Dec 2012 → Mar 2013	ocular hypertension, open-angle glaucoma	Adapt Produtos Oftalmológicos Ltda.	Withdrawn	No outcome recorded
Phase 3	NCT00912054	Mar 2010 → May 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Terminated	No outcome recorded
Phase 3	NCT01156012	Sep 2009 → Dec 2010	glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT00716859	Jul 2008 → Nov 2009	glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00383019	Nov 2006 → Oct 2007	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00546286	May 2006 → Aug 2007	ocular hypertension, open-angle glaucoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00277498	Dec 2005 → Jun 2007	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00230763	Sep 2005 → Oct 2007	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00159653	Jul 2005 → Jun 2007	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00219596	Jun 2005 → Sep 2006	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00051142	Feb 2001 → Jun 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00051155	Jan 2001 → Jul 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00051181	Jan 2000 → Jun 2003	chronic closed-angle glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00800267	Jul 1997 → Jun 1999	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00751127	Jan 1993 → Feb 1994	ocular hypertension, open-angle glaucoma	Pfizer	Completed	No outcome recorded
Phase 3	NCT00751049	Dec 1992 → Dec 1993	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00751062	Nov 1992 → Dec 1993	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00283764	—	ocular hypertension, open-angle glaucoma	Viatris Inc.	Withdrawn	No outcome recorded
Phase 3	NCT02154217	? → Dec 2004	glaucoma	University of Milan	Completed	No outcome recorded

Phase 430 trials
Phase 4	NCT04401982	Jul 2026 → Mar 2027 expected	borderline glaucoma, ocular hypertension	University of Maryland, Baltimore	Recruiting	No outcome recorded
Phase 4	NCT05606796	Dec 2022 → Aug 2023	—	Uzoma Chinyei Joan	Unknown	No outcome recorded
Phase 4	NCT04702789	Oct 2021 → Nov 2023	ocular hypertension, open-angle glaucoma	Laboratorios Sophia S.A de C.V.	Terminated	No outcome recorded
Phase 4	NCT04412096	Nov 2020 → May 2025	glaucoma, ocular hypertension	Ohio State University	Completed	No outcome recorded
Phase 4	NCT04098861	Jan 2019 → Aug 2020	open-angle glaucoma	Universiti Kebangsaan Malaysia Medical Centre	Unknown	No outcome recorded
Phase 4	NCT03331770	Jan → Oct 2017	open-angle glaucoma	Laboratorios Poen	Completed	No outcome recorded
Phase 4	NCT02792803	Sep 2015 → Apr 2017	ocular hypertension, open-angle glaucoma	Dr. David Yan	Unknown	No outcome recorded
Phase 4	NCT01927406	Jun 2014 → Dec 2016	endocrine exophthalmos, glaucoma, ocular hypertension	Stanford University	Withdrawn	No outcome recorded
Phase 4	NCT02047630	Jan → Dec 2014	ocular hypertension, open-angle glaucoma	CHU de Quebec-Universite Laval	Terminated	No outcome recorded
Phase 4	NCT03966560	Jan 2014 → Jan 2015	open-angle glaucoma	Afyon Kocatepe University Hospital	Completed	No outcome recorded
Phase 4	NCT02017327	Dec 2013 → Jul 2016	ocular hypertension, open-angle glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 4	NCT01975714	Oct 2013 → Feb 2015	glaucoma, ocular hypertension	Association for Innovation and Biomedical Research on Light and Image	Completed	No outcome recorded
Phase 4	NCT01677507	Aug 2012 → Aug 2016	glaucoma	University of Michigan	Completed	No outcome recorded
Phase 4	NCT01535768	Feb 2012 → Jun 2018	glaucoma	Credit Valley EyeCare	Unknown	No outcome recorded
Phase 4	NCT01978015	Oct 2011 → Jul 2012	anterior uveitis, cystoid macular edema	University of Campinas, Brazil	Completed	No outcome recorded
Phase 4	NCT01225653	Nov 2010 → Dec 2014	diabetic retinopathy	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT00941525	Sep 2009 → Jul 2014	ocular hypertension, open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00798694	Nov 2008 → Jan 2011	glaucoma	Wills Eye	Completed	No outcome recorded
Phase 4	NCT00468988	May → Jul 2007	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00397241	Sep 2006 → Dec 2007	open-angle glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00329095	Dec 2005 → Apr 2006	glaucoma, ocular hypertension	Robin, Alan L., M.D.	Completed	No outcome recorded
Phase 4	NCT00273481	Sep 2005 → Apr 2007	ocular hypertension, open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00140049	Jul 2005 → Jul 2006	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00304785	May 2005 → Oct 2007	ocular hypertension, open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00273429	Apr → Dec 2005	ocular hypertension, open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00224289	Mar 2005 → Apr 2009	glaucoma	Yale University	Completed	No outcome recorded
Phase 4	NCT00647101	Dec 2003 → Feb 2005	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00308945	Nov 2003 → Feb 2005	open-angle glaucoma	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT00143208	May 2003 → Apr 2006	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00140062	Feb 2002 → Apr 2006	ocular hypertension, open-angle glaucoma	Pfizer	Completed	No outcome recorded

Phase not applicable11 trials
—	NCT05850936	Jun 2023 → Nov 2026 expected	myopia	Sun Yat-sen University	Active not recruiting	No outcome recorded
—	NCT04891588	Mar → Sep 2021	ocular hypertension, open-angle glaucoma	University Hospital Centre Zagreb	Unknown	No outcome recorded
—	NCT04296916	Apr 2020 → Oct 2024	borderline glaucoma, myopia	Sun Yat-sen University	Unknown	No outcome recorded
—	NCT04737928	Apr 2018 → Jan 2019	open-angle glaucoma	Santen Pharmaceutical (Taiwan) Co., LTD	Completed	No outcome recorded
—	NCT02522039	May → Nov 2014	glaucoma	Glostrup University Hospital, Copenhagen	Completed	No outcome recorded
—	NCT02656979	Dec 2013 → Sep 2019	glaucoma	Umeå University	Unknown	No outcome recorded
—	NCT01430923	Sep 2011 → May 2012	ocular hypertension, open-angle glaucoma	Aurolab	Unknown	No outcome recorded
—	NCT01084902	Feb → Sep 2010	ocular hypertension	Peking University First Hospital	Unknown	No outcome recorded
—	NCT01361841	Jan 2009 → Jan 2012	ocular hypertension, open-angle glaucoma	Centre de recherche du Centre hospitalier universitaire de Sherbrooke	Unknown	No outcome recorded
—	NCT00619034	Sep 2007 → Dec 2010	diabetic retinopathy	University of Aarhus	Completed	No outcome recorded
—	NCT00440336	Oct 2006 → ?	open-angle glaucoma	Advanced Glaucoma Specialists	Unknown	No outcome recorded

Also used as a comparator or background therapy in 116 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07425535 Background	Jun 2026 → Mar 2028 expected	glaucoma	Johns Hopkins University	Recruiting	No outcome recorded
Phase 14 trials
Phase 1	NCT04500574 Comparator	Apr 2024 → Oct 2025	glaucoma, ocular hypertension	Massachusetts Eye and Ear Infirmary	Terminated	No outcome recorded
Phase 1	NCT02531152 Comparator	Sep 2015 → Apr 2016	open-angle glaucoma	Sanofi	Completed	No outcome recorded
Phase 1	NCT02108288 Comparator	Apr → May 2014	glaucoma, ocular hypertension	Otsuka Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01180062 Comparator	Jan 2011 → Jun 2014	ocular hypertension, open-angle glaucoma	Daniel Moore	Terminated	No outcome recorded
Phase 1/25 trials
Phase 1/2	NCT06239324 Comparator	Feb → Apr 2024	alopecia areata	Egymedicalpedia	Unknown	No outcome recorded
Phase 1/2	NCT04761705 Comparator	Mar 2021 → Mar 2025	ocular hypertension, open-angle glaucoma	JeniVision, Inc.	Suspended	No outcome recorded
Phase 1/2	NCT01410188 Comparator	Sep 2011 → Oct 2012	ocular hypertension, open-angle glaucoma	Kubota Vision Inc.	Completed	No outcome recorded
Phase 1/2	NCT00868894 Comparator	Mar 2009 → May 2010	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 1/2	NCT00846989 Comparator	Jan → Apr 2009	ocular hypertension, open-angle glaucoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 222 trials
Phase 2	NCT06441643 Comparator	Sep 2024 → Nov 2025	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT04405245 Background	Jun → Nov 2020	ocular hypertension, open-angle glaucoma	EyePoint Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT03657797 Comparator	Aug 2018 → Aug 2019	ocular hypertension, open-angle glaucoma	Nicox Ophthalmics, Inc.	Completed	No outcome recorded
Phase 2	NCT03216902 Comparator	Jul 2017 → Feb 2018	open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT02829996 Comparator	Aug 2016 → May 2017	ocular hypertension, open-angle glaucoma	Inotek Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT02466399 Comparator	Jul 2015 → Apr 2016	glaucoma	Peregrine Ophthalmic	Completed	No outcome recorded
Phase 2	NCT02179008 Comparator	Jun 2014 → Jan 2015	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT02083289 Comparator	May → Dec 2014	ocular hypertension, open-angle glaucoma	Ono Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT01917383 Background	Aug 2013 → Aug 2014	ocular hypertension, open-angle glaucoma	Inotek Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT01896180 Comparator	Jul 2013 → Jan 2014	ocular hypertension, open-angle glaucoma	Alleanza Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01868126 Comparator	May → Aug 2013	open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT01731002 Comparator	Nov 2012 → May 2013	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01318252 Comparator	Jun → Oct 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT01302249 Background	Feb → Dec 2011	glaucoma, ocular hypertension	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01223378 Comparator	Dec 2010 → Dec 2011	—	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 2	NCT01887223 Comparator	May 2010 → Jun 2011	open-angle glaucoma	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 2	NCT00761709 Comparator	Jul → Oct 2009	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT00650338 Comparator	Mar → Sep 2008	ocular hypertension, open-angle glaucoma	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT00620256 Background	Nov 2007 → Jul 2008	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT00441883 Comparator	Mar 2007 → Feb 2008	exfoliation syndrome, ocular hypertension, open-angle glaucoma	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 2	NCT00287521 Comparator	Nov 2005 → Feb 2006	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 2	NCT00069706 Comparator	Jul → Oct 2003	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT07354516 Comparator	Mar → Jul 2026 overdue	ocular hypertension, open-angle glaucoma	Qlaris Bio, Inc.	Active not recruiting	No outcome recorded
Phase 2/3	NCT05513924 Comparator	Mar → Nov 2022	vitiligo	South Valley University	Completed	No outcome recorded
Phase 2/3	NCT03611348 Comparator	Sep 2018 → Sep 2019	vitiligo	Sohag University	Unknown	No outcome recorded
Phase 2/3	NCT02623738 Comparator	Dec 2015 → Feb 2017	ocular hypertension, open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 322 trials
Phase 3	NCT06666855 Comparator	Nov 2024 → Aug 2026 overdue	ocular hypertension, open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Active not recruiting	No outcome recorded
Phase 3	NCT05583474 Comparator	Sep 2022 → Nov 2024	open-angle glaucoma	Otsuka Beijing Research Institute	Completed	No outcome recorded
Phase 3	NCT05495061 Comparator	Aug 2022 → Apr 2023	ocular hypertension, open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT05165290 Comparator	Nov 2021 → Sep 2022	ocular hypertension	TearClear Corp	Unknown	No outcome recorded
Phase 3	NCT04630808 Comparator	Nov 2020 → Apr 2025	ocular hypertension, open-angle glaucoma	Nicox Ophthalmics, Inc.	Completed	No outcome recorded
Phase 3	NCT04445519 Comparator	Jun 2020 → Sep 2022	ocular hypertension, open-angle glaucoma	Nicox Ophthalmics, Inc.	Completed	No outcome recorded
Phase 3	NCT03762369 Comparator	Dec 2018 → Feb 2022	ocular hypertension, open-angle glaucoma	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 3	NCT02822742 Background	Jul 2016 → Apr 2017	open-angle glaucoma	Santen Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03419975 Comparator	Apr 2016 → Dec 2017	ocular hypertension, open-angle glaucoma	Taejoon Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02674854 Comparator	Feb 2016 → Mar 2017	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02558400 Comparator	Sep 2015 → May 2017	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02278614 Comparator	Dec 2014 → Nov 2015	ocular hypertension, open-angle glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT02105272 Comparator	Apr 2014 → Mar 2015	glaucoma, ocular hypertension	Otsuka Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01433900 Comparator	May 2012 → May 2013	glaucoma	Paolo Fogagnolo	Unknown	No outcome recorded
Phase 3	NCT00872651 Comparator	Jan 2010 → Nov 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00892762 Comparator	Jun 2009 → May 2011	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00761319 Comparator	Oct 2008 → Sep 2009	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00690794 Comparator	Jul 2008 → May 2009	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00293800 Comparator	Jul 2004 → Dec 2005	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00293787 Comparator	Jun 2004 → Aug 2005	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00311389 Comparator	Jan 2003 → Sep 2004	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 3	NCT00856622 Comparator	Aug 1997 → Jun 1999	ocular hypertension, open-angle glaucoma	Viatris Inc.	Completed	No outcome recorded

Phase 446 trials
Phase 4	NCT07465913 Comparator	May 2026 → May 2027 expected	glaucoma	Eye Centers of Southeast Texas	Recruiting	No outcome recorded
Phase 4	NCT07325240 Comparator	Nov 2025 → Jul 2027 expected	ocular hypertension, open-angle glaucoma	Mayo Clinic	Recruiting	No outcome recorded
Phase 4	NCT06883123 Comparator	May 2025 → Apr 2026 overdue	open-angle glaucoma	Prairie Eye Center	Recruiting	No outcome recorded
Phase 4	NCT06407973 Comparator	Aug 2024 → Jan 2025	open-angle glaucoma	Sight Sciences, Inc.	Terminated	No outcome recorded
Phase 4	NCT06369077 Comparator	Apr → Jul 2024	open-angle glaucoma	CT Glaucoma Associates	Terminated	No outcome recorded
Phase 4	NCT04957329 Comparator	Sep 2021 → Dec 2026 expected	glaucoma, ocular hypertension	Rigshospitalet, Denmark	Recruiting	No outcome recorded
Phase 4	NCT04811326 Comparator	Jan 2021 → Feb 2024	vitiligo	Shaimaa Fawzy Abdel-rady Abdel-latif	Unknown	No outcome recorded
Phase 4	NCT03648229 Comparator	Sep 2019 → Jun 2022	open-angle glaucoma	West Virginia University	Withdrawn	No outcome recorded
Phase 4	NCT03949244 Comparator	Aug 2019 → Oct 2020	open-angle glaucoma	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT04743622 Comparator	Apr 2019 → Jun 2020	glaucoma, ocular hypertension	CHA University	Completed	No outcome recorded
Phase 4	NCT04164459 Comparator	Dec 2018 → Dec 2019	glaucoma	Taejoon Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT04178863 Comparator	Jul 2018 → Dec 2019	glaucoma	Intuor Technologies, Inc.	Unknown	No outcome recorded
Phase 4	NCT02585375 Comparator	Sep 2015 → Sep 2023	glaucoma, ocular hypertension	Medical University of Vienna	Unknown	No outcome recorded
Phase 4	NCT02419508 Background	Aug 2015 → Feb 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT02350023 Comparator	Sep 2014 → Mar 2015	alopecia areata	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 4	NCT01937312 Background	Oct 2013 → May 2014	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01704989 Comparator	Jun 2012	glaucoma	Nova Scotia Health Authority	Withdrawn	No outcome recorded
Phase 4	NCT01525173 Comparator	Jan → Oct 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01580254 Comparator	Jun 2011 → Jun 2012	ocular hypertension	University of Catanzaro	Unknown	No outcome recorded
Phase 4	NCT01162603 Comparator	Mar 2011 → Apr 2012	ocular hypertension, open-angle glaucoma	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Completed	No outcome recorded
Phase 4	NCT01263444 Background	Mar 2011 → Apr 2013	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01315574 Comparator	Feb 2011 → Dec 2013	glaucoma	Massachusetts Eye and Ear Infirmary	Terminated	No outcome recorded
Phase 4	NCT01253902 Comparator	Dec 2010 → Oct 2011	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01243567 Comparator	Jun 2010 → Feb 2012	open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01448837 Comparator	Apr 2010 → Mar 2011	glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT01151904 Background	Nov 2009 → Feb 2012	angle-closure glaucoma	Allergan	Terminated	No outcome recorded
Phase 4	NCT00972426 Background	Oct 2009 → Aug 2010	glaucoma	Taiwan Otsuka Pharm. Co., Ltd	Completed	No outcome recorded
Phase 4	NCT00887029 Comparator	Jan → Nov 2009	ocular hypertension, open-angle glaucoma	Ophthalmic Consultants Centres, Canada	Completed	No outcome recorded
Phase 4	NCT00796198 Comparator	Dec 2008 → Jun 2009	glaucoma	University of Turin, Italy	Unknown	No outcome recorded
Phase 4	NCT00811564 Comparator	Dec 2008 → Jan 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00798759 Comparator	Dec 2008 → May 2009	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00799682 Comparator	Oct 2008 → Jan 2011	dry eye syndrome	Ophthalmic Consultants of Long Island	Completed	No outcome recorded
Phase 4	NCT00708422 Comparator	Jul 2008 → Aug 2009	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00735449 Comparator	Jul 2008 → Dec 2009	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00757835 Comparator	May 2008 → Mar 2009	glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT00705757 Comparator	Mar 2008 → Apr 2011	glaucoma, hyperpigmentation of the skin	Summa Health System	Completed	No outcome recorded
Phase 4	NCT00541242 Comparator	Dec 2007 → Aug 2008	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00759941 Background	Oct 2007 → Jul 2009	glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00539526 Comparator	Sep 2007 → Jul 2008	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00906594 Background	Sep 2007 → Jan 2008	glaucoma	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT00527592 Comparator	May 2007 → Aug 2008	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00440141 Background	Jul 2006 → Mar 2007	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00847483 Comparator	Jan → Aug 2002	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT01655758 Comparator	Jan 2002 → Dec 2003	ocular hypertension	University of Parma	Completed	No outcome recorded
Phase 4	NCT00347841 Background	—	glaucoma	Innovative Medical	Completed	No outcome recorded
Phase 4	NCT00348400 Background	—	glaucoma	Innovative Medical	Completed	No outcome recorded

Phase not applicable12 trials
—	NCT05241938 Comparator	Sep 2021 → Dec 2022	ocular hypertension, open-angle glaucoma	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
—	NCT03318146 Comparator	Jun 2018 → Jun 2019	glaucoma, ocular hypertension	Shaare Zedek Medical Center	Unknown	No outcome recorded
—	NCT03480906 Comparator	Mar 2018	—	Eyenovia Inc.	Completed	No outcome recorded
—	NCT01639807 Comparator	Oct 2011 → Oct 2013	open-angle glaucoma	Aurolab	Unknown	No outcome recorded
—	NCT01201551 Comparator	Jun 2011 → Nov 2013	vascular disorder	University Hospital, Basel, Switzerland	Completed	No outcome recorded
—	NCT01175902 Comparator	Mar 2011 → Oct 2014	low tension glaucoma	The Catholic University of Korea	Completed	No outcome recorded
—	NCT00815373 Comparator	Dec 2008 → Dec 2011	ocular hypertension, open-angle glaucoma	Meir Medical Center	Withdrawn	No outcome recorded
—	NCT00402493 Comparator	Dec 2006 → Mar 2008	glaucoma, ocular hypertension	Philadelphia Eye Associates	Completed	No outcome recorded
—	NCT00567788 Comparator	Jul 2006 → Jul 2008	chronic closed-angle glaucoma	Singapore National Eye Centre	Unknown	No outcome recorded
—	NCT00712400 Comparator	Jun 2005 → Sep 2009	—	Medical University of Vienna	Completed	No outcome recorded
—	NCT00187577 Comparator	Jun 2005 → Feb 2006	alopecia areata	University of California, San Francisco	Completed	No outcome recorded
—	NCT00804115 Comparator	Aug 2000 → Sep 2007	exfoliation syndrome, ocular hypertension	The New York Eye & Ear Infirmary	Unknown	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2015-10-01	Otsuka Pharmaceutical Development & Commercialization, Inc.	New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension otsuka.co.jp ↗
2011-06-14	Pfizer	pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma pfizer.com ↗

Evidence & citations 25 cited values

Every value below carries the sentence it was read from. 228 sources stand behind the page.

Field	Value	Cited text
Known as	latanoprost	“To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure...” NCT00159653 ↗ 213 “a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs...” NCT01535768 ↗ “prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye.” NCT01927406 ↗ “Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days).” NCT04702789 ↗ “TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%).” NCT07435012 ↗ “PURPOSE: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z).” PMID 28617732 ↗ Nov 2018 “This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment.” NCT00143208 ↗ “A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension.” NCT00751127 ↗ “OBJECTIVE: To assess the efficacy and safety of fixed-combination latanoprost-timolol (FCLT) vs latanoprost or timolol monotherapy.” PMID 20142538 ↗ Feb 2010 “IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.” NCT05850936 ↗ “Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use.” NCT02017327 ↗ “The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt)” NCT00140049 ↗ “Fixalpost ( T2347), 50 micrograms/ml latanoprost + 5 mg/ml timolol maleate eye drops, solution in single-dose container” NCT04891588 ↗ “Xalatan (latanoprost) has been marketed for nearly 15 years, and its performance in reducing IOP is well established” NCT03318146 ↗ “Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.” NCT04133311 ↗ “T-2345 nonpreserved ophthalmic solution (latanoprost 0.005%) in comparison to Xalatan® (latanoprost 0.005%)” NCT02059278 ↗ “Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed” NCT05241938 ↗ “Different Formulations (E1 and E2) of the Latanoprost Punctal Plug Delivery System (L-PPDS)” NCT00967811 ↗ “Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing.” NCT06369077 ↗ “known formulation of Latanoprost 0.005% (GAAP Ofteno®, Laboratorios Sophia, Mexico)” NCT02801617 ↗ “T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops” NCT02278614 ↗ “XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution” NCT00912054 ↗ “Topical application of netarsudil 0.02% with latanoprost 0.005%” NCT04234932 ↗ “Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day” NCT04448223 ↗ “Topical Prostaglandin, Latanoprost Ophthalmic Solution” NCT00799682 ↗ “Latanoprost 0.005% eye drops will be the first choice.” NCT04296916 ↗ “Treatment will be initiated with latanoprost 0.005%.” NCT01704989 ↗ “XALATAN® (Latanoprost ophthalmic solution, 0.005%)” NCT02419508 ↗ “Monoprost (preservative-free latanoprost eye drop)” NCT04743622 ↗ “Subconjunctival liposomal Latanoprost (POLAT-001)” NCT02466399 ↗ “latanoprost 0.005%, one rop once daily in evening” NCT00383019 ↗ “Latanoprost Travaprost Bimatoprost Tafluprost” NCT03292796 ↗ “Sustained release of latanoprost into the eye” NCT02129673 ↗ “a prostaglandin (PG) (latanoprost) was added” PMID 20874498 ↗ Oct 2010 “Latanoprost Ophthalmic Solution 0.005%” NCT02057575 ↗ “BAK-preserved latanoprost” NCT04957329 ↗ “Xalatan (latanoprost)” NCT00440336 ↗ “Latanoprost” NCT02623738 ↗ “Latanoprost” NCT06441643 ↗ “Latanoprost” NCT04205201 ↗ “Latanoprost” NCT01263444 ↗ NCT04401982 ↗ NCT00140062 ↗ NCT00440141 ↗ NCT00397241 ↗ NCT06883123 ↗ NCT05165290 ↗ NCT00872651 ↗ NCT01975714 ↗ NCT01180062 ↗ NCT00906594 ↗ NCT02829996 ↗ NCT04737928 ↗ NCT06666855 ↗ NCT02179008 ↗ NCT03067415 ↗ NCT05513924 ↗ NCT06407973 ↗ NCT01978015 ↗ NCT00219596 ↗ NCT01481051 ↗ NCT06441643 ↗ NCT01527682 ↗ NCT01151904 ↗ NCT01481077 ↗ NCT01868126 ↗ NCT02047630 ↗ NCT00539526 ↗ NCT06629129 ↗ NCT00069706 ↗ NCT01315574 ↗ NCT03216902 ↗ NCT07016113 ↗ NCT03611348 ↗ NCT01175902 ↗ NCT00572936 ↗ NCT00972426 ↗ NCT00527592 ↗ NCT00051142 ↗ NCT05606796 ↗ NCT00051155 ↗ NCT00804115 ↗ NCT00051181 ↗ NCT04630808 ↗ NCT00820300 ↗ NCT02522039 ↗ NCT07354516 ↗ NCT06960629 ↗ NCT00735449 ↗ NCT03293992 ↗ NCT01896180 ↗ NCT00759941 ↗ NCT01410188 ↗ NCT01987323 ↗ NCT01229982 ↗ NCT00619034 ↗ NCT02622334 ↗ NCT02585375 ↗ NCT00821002 ↗ NCT02390284 ↗ NCT06730516 ↗ NCT03949244 ↗ NCT00293800 ↗ NCT00293787 ↗ NCT01433900 ↗ NCT02623738 ↗ NCT03648229 ↗ NCT01379144 ↗ NCT04500574 ↗ NCT01302249 ↗ NCT04060758 ↗ NCT01162603 ↗ NCT00647101 ↗ NCT00846989 ↗ NCT00800267 ↗ NCT00757835 ↗ NCT01430923 ↗ NCT00273429 ↗ NCT04761705 ↗ NCT00716859 ↗ NCT02154217 ↗ NCT00273481 ↗ NCT05583474 ↗ NCT04405245 ↗ NCT00287521 ↗ NCT04178863 ↗ NCT00855517 ↗ NCT03419975 ↗ NCT04811326 ↗ NCT05495061 ↗ NCT02108288 ↗ NCT01639807 ↗ NCT00868894 ↗ NCT02656979 ↗ NCT01580254 ↗ NCT01318252 ↗ NCT00441883 ↗ NCT01225653 ↗ NCT00311389 ↗ NCT00941525 ↗ NCT01060579 ↗ NCT03480906 ↗ NCT01201551 ↗ NCT00690794 ↗ NCT00595101 ↗ NCT01731002 ↗ NCT00815373 ↗ NCT07425535 ↗ NCT01361841 ↗ NCT02558400 ↗ NCT01084902 ↗ NCT02531152 ↗ NCT06964191 ↗ NCT07465913 ↗ NCT00887029 ↗ NCT01721707 ↗ NCT00230763 ↗ NCT02822742 ↗ NCT00224289 ↗ NCT01973114 ↗ NCT01223378 ↗ NCT03284853 ↗ NCT00712400 ↗ NCT00847483 ↗ NCT00856622 ↗ NCT00761709 ↗ NCT00638742 ↗ NCT01677507 ↗ NCT01037036 ↗ NCT00811564 ↗ NCT00541242 ↗ NCT00187577 ↗ NCT00708422 ↗ NCT04098861 ↗ NCT02674854 ↗ NCT00892762 ↗ NCT02083289 ↗ NCT00308945 ↗ NCT01448837 ↗ NCT01426464 ↗ NCT00761319 ↗ NCT03657797 ↗ NCT00304785 ↗ NCT02014142 ↗ NCT04445519 ↗ NCT02350023 ↗ NCT00650702 ↗ NCT01917383 ↗ NCT00348400 ↗ NCT00620256 ↗ NCT01243567 ↗ NCT03966560 ↗ NCT00934089 ↗ NCT00845299 ↗ NCT01254370 ↗ NCT00572455 ↗ NCT00402493 ↗ NCT03762369 ↗ NCT00650338 ↗ NCT04412096 ↗ NCT03331770 ↗ NCT06239324 ↗ NCT00798759 ↗ NCT05790941 ↗ NCT02105272 ↗ NCT07325240 ↗ NCT00567788 ↗ NCT00347841 ↗ NCT01525173 ↗ NCT00329095 ↗ NCT01655758 ↗ NCT01253902 ↗ NCT00579969 ↗ NCT00705757 ↗
Known as	alphagan-P	“alphagan 0.2% or alphagan-P 0.15% will be added.” NCT04296916 ↗
Known as	Catioprost	“Catioprost® (Unpreserved Latanoprost 0.005% Emulsion)” NCT01254370 ↗
Known as	D565H	“D565H(Latanoprost 25㎍/㎖)” NCT03067415 ↗
Known as	GAAP Ofteno	“known formulation of Latanoprost 0.005% (GAAP Ofteno®, Laboratorios Sophia, Mexico)” NCT02801617 ↗
Known as	GALAXIA	“patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months” NCT01580254 ↗
Known as	IOPIZE	“patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months” NCT01580254 ↗
Known as	LAT	“Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control” NCT05165290 ↗
Known as	Latanoprost (Xalatan)	“Latanoprost (Xalatan)” NCT00187577 ↗
Known as	Latanoprost RATIOPHARM	“patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months” NCT01580254 ↗
Known as	Latanoprost T	“Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).” NCT01361841 ↗
Known as	latanprost	“Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.” NCT00690794 ↗
Known as	LUDPF	“Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.” NCT01975714 ↗
Known as	Monoprost	“Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use.” NCT02017327 ↗ 1 “Monoprost (preservative-free latanoprost eye drop)” NCT04743622 ↗
Known as	PA5108	“PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant” NCT04060758 ↗
Known as	PhXA41	“A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension.” NCT00751127 ↗ 2 NCT00751049 ↗ NCT00751062 ↗
Known as	POLAT-001	“Subconjunctival liposomal Latanoprost (POLAT-001)” NCT02466399 ↗
Known as	T-2345	“T-2345 nonpreserved ophthalmic solution (latanoprost 0.005%)” NCT02059278 ↗ 2 NCT01494753 ↗ NCT01156012 ↗
Known as	travoprost z	“prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye.” NCT01927406 ↗
Known as	Xalatan	“A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary...” PMID 22607109 ↗ May 2012 27 “Researchers want to find out more about how 2 drugs called Cosopt (dorzolamide hydrochloride and timolol maleate) and Xalatan (latanoprost) can help people with these conditions.” NCT00440336 ↗ “XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension.” NCT03318146 ↗ “Latanoprost (Xalatan\) is a prostaglandin F2\ analogue which is believed to reduce IOP by increasing the outflow of aqueous humor.” NCT00815373 ↗ “dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days” NCT01937312 ↗ “Latanoprost (Xalatan) ophthalmic solution compared to bimatoprost (Lumigan) ophthalmic solution” NCT00187577 ↗ “Latanoprost( xalatan 0.005% ) is applied to the treated area for all participants.” NCT06239324 ↗ “Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year” NCT00705757 ↗ “carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)” NCT00972426 ↗ “Latanoprost 0.005% Ophthalmic Solution (XALATAN)” NCT00293800 ↗ “Latanoprost 0.005% ophthalmic solution (Xalatan)” NCT00759941 ↗ “Xalatan (preserved latanoprost eye drop)” NCT04743622 ↗ “Latanoprost(Xalatan) eye drops” NCT00402493 ↗ “Xalatan® (latanoprost 0.005%)” NCT02059278 ↗ “Latanoprost 0.005%, Xalatan®” NCT00712400 ↗ “latanoprost 0.005% (Xalatan)” NCT00140062 ↗ “Drug: Latanoprost (Xalatan)” NCT06730516 ↗ “latanoprost = Xalatan®” NCT00541242 ↗ “Xalatan” NCT01887223 ↗ NCT00468988 ↗ NCT01037036 ↗ NCT00143429 ↗ NCT04164459 ↗ NCT00798694 ↗ NCT00283764 ↗ NCT02792803 ↗ NCT00796198 ↗ NCT00465621 ↗
Known as	XALATAN (Latanoprost ophthalmic solution, 0.005%)	“XALATAN® (Latanoprost ophthalmic solution, 0.005%)” NCT02419508 ↗
Known as	XalatanTM	“All patients treated with topical Latanoprost 0.005% (XalatanTM, 2.5 ml eye drops, Pfizer)” NCT06629129 ↗
Action	Activate	“the FP agonist Xalatan” PMID 27649982 ↗ Sep 2016
Modality	Small molecule	“Latanoprost is a synthetic prodrug of 17-phenyl-substituted prostaglandin F2α analog.” NCT00712400 ↗
Route	Topical	“Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.” NCT00187577 ↗